Active warning — SupplementIndex Safety Review: FDA warning. WADA banned.
Updated: 2026-05-29 · v2.0 · Prof. G. Pkhakadze, MD, MPH, PhDCiteEditorial
Read the full Methylsynephrine / Oxilofrine evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.
5
Avoid
Methylsynephrine / Oxilofrine
p-Hydroxyephedrine
Use with CautionLimitedRestricted
RDA
NOT recommended
Target
N/A
Upper limit
No safe dose
Products
—
Dosage by population group — reference
HIGH RISK — see overview [1]
ℹ️ Not obtained from food. Not applicable — this substance is not a dietary nutrient and should not be consumed as food.
Lab interpreter
ℹ️ No validated blood test. There is no established laboratory test to assess status or guide dosing for this ingredient. Clinical response and symptoms are the practical guide.
⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
Methylsynephrine/oxilofrine is a WADA-BANNED sympathomimetic found illegally in supplements. Stronger cardiovascular effects than bitter orange synephrine. Athletes have received bans from contaminated supplements. FDA: not a legitimate dietary ingredient. Any product containing this is adulterated [1].
1 How much do I need?
Adults: Specific dosage data under clinical review
Elderly: Specific dosage data under clinical review
Pregnancy: See guidance
CONTRAINDICATED [1].
Pediatric: See guidance
NOT recommended [1].
Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
Vegan: Standard dose

How to take

Timing: See overview [1].
With food: See overview [1].
Avoid: See overview [1].
2 Which form?
FormBioavailabilityVeganCost
['See overview', 'restricted', 'See overview [1].']StandardCheck label
3 Common questions
Key safety ▼
Methylsynephrine/oxilofrine is a WADA-BANNED sympathomimetic found illegally in supplements. Stronger cardiovascular effects than bitter orange synephrine. Athletes have received bans from contaminated supplements. FDA: not a legitimate dietary ingredient. Any product containing this is adulterated [1].
4 Clinical evidence

Strong

See overview [1]. HIGH

Moderate

See overview [1]. MODERATE

Insufficient

See overview [1]. LOW
5 Safety, toxicity & adverse events

Absolute contraindications

✕ Should not be used — an unapproved stimulant drug linked to cardiac arrest, causing hypertension and arrhythmia
✕ Cardiovascular disease

Relative

Other stimulants and MAOIs

Red flags

● HIGH RISK — see overview [1]
6 Interactions
7 Cite this page
Vancouver: Pkhakadze G. Methylsynephrine / Oxilofrine — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Nov 15]. Available from: https://supplement.ge/ingredients/methylsynephrine-oxilofrine/
APA 7th: Pkhakadze, G. (2026). Methylsynephrine / Oxilofrine — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/methylsynephrine-oxilofrine/
Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: May 2027
References: 1 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Methylsynephrine / Oxilofrine — Safety Profile." supplement.ge, PHIG, 2026. https://supplement.ge/ingredients/methylsynephrine-oxilofrine/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG